Drug Profile

BW 01

Alternative Names: BW-01

Latest Information Update: 30 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Argo Biopharma
Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Cardiovascular disorders; Hypertriglyceridaemia

Most Recent Events

30 Jan 2025 Phase-II clinical trials in Cardiovascular disorders (Parenteral), before January 2025 (Argo Biopharma pipeline, January 2025)
07 Feb 2024 BW 01 is available for licensing as of 07 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Aargo Biopharma website January 2024)
31 Jan 2024 Argo Biopharma plans a phase II trial for Cardiovascular disorders in the first half of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com